MRI reveals how weight loss drugs reshape organs in severely obese teens

NCT ID NCT07702825

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study uses MRI scans to measure how weight loss treatments affect fat in the liver, pancreas, and other organs of adolescents aged 12 to 18 with severe obesity. Researchers compare two approaches: GLP-1 receptor agonist drugs combined with lifestyle changes versus lifestyle changes alone. Participants undergo MRI scans at the start and after 9 months to track changes in organ fat and body composition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonists (a class of weight-loss drugs) plus lifestyle changes
What this could lead to
If successful, this could show that combining GLP-1 drugs with lifestyle changes improves organ health in teens with severe obesity, pointing toward better treatment strategies.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to all teens. The MRI scans may not detect meaningful changes, and the drugs can cause side effects like nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity Obesity obesity disorder Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Alder Hey Children's hospital

    RECRUITING

    Liverpool, Merseyside, L122AP, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.